| Literature DB >> 28570592 |
Thandiwe A L Dlamini1, Peter J Heering2, Tawanda Chivese3, Brian Rayner1.
Abstract
AIM: To study the demographics and outcome of acute kidney injury (AKI) at Groote Schuur Hospital, Cape Town, South Africa. METHODS ANDEntities:
Mesh:
Year: 2017 PMID: 28570592 PMCID: PMC5453519 DOI: 10.1371/journal.pone.0177460
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Precipitants and causes of AKI.
| AKI precipitant or cause | Total (% of 366) |
|---|---|
| Pneumonia | 42(11.5%) |
| Pyelonephritis/urosepsis | 27(7.4%) |
| Sepsis post trauma | 24 (6.6%) |
| Acute gastrointestinal tract pathology with sepsis | 24 (6.6%) |
| Soft tissue sepsis | 6 (1.6%) |
| Bacterial gastroenteritis | 4 (1.1%) |
| Meningitis | 2 (0.55%) |
| Septic arthritis | 2 (0.9%) |
| Septic abortion (also later in this table) | 1 (0.27%) |
| Other/miscellaneous sites of sepsis | 90 (24.6%) |
| IV contrast | 50 (13.7%) |
| Tenofovir | 23 (6.3%) |
| Aminoglycosides | 10 (2.7%) |
| Herbal toxins | 7 (1.9%) |
| 47 (12.8%) | |
* Other exogenous toxins
Non-steroidal anti-inflammatory drugs (5), ethylene glycol (4), methamphetamine locally called ‘Tik’ (2), heroine (1), angiotensin converting enzyme inhibitor (1), methanol (1), antipsychotic medication related rhabdomyolysis (1), ethanol related organ dysfunction (7). The remainder were mostly assessed as related to antibiotics including amphotericin B, colistin, cotrimoxazole and rifampicin.
Pathological diagnoses of AKI (including biopsy proven cases).
| Variable | Total (% of 366) |
|---|---|
| ATN predominant (including 11 histological diagnoses) | 272 (72.1%) |
| Glomerulonephritis/vasculitis (including 1 clinical diagnosis) | 20 (5.5%) |
| Pyelonephritis (including 5 histological diagnoses) | 19 (5.2%) |
| Obstruction | 17 (4.6%) |
| Acute interstitial nephritis (including 2 histological diagnoses) | 14 (3.8%) |
| Pre-eclampsia | 14 (3.8%) |
| Granulomas | 8 (2.2%) |
| Malignant hypertension (including 3 histological diagnoses) | 7 (1.9%) |
| Multiple myeloma | 3 (0.82%) |
30 and 90 day mortality and associated patient characteristics.
| 30 day mortality, n (%) | 90 day mortality, n (%) | |||||||
|---|---|---|---|---|---|---|---|---|
| Department | Medical | Surgical | Obstetrics & Gynaecology | Overall | Medical | Surgical | Obstetrics & Gynaecology | Overall |
| 48/120 (40.0) | 28/73 (38.4) | 1/12 (8.3) | 77/205 (37.6) | 56/120 (46.7) | 37/73 (50.7) | 3/12 (25.0) | 96/205 (46.8) | |
| 34/89 (38.2) | 43/105 (41.0) | 1/8 (12.5) | 78/202 (38.6) | 35/89 (39.3) | 54/105 (51.4) | 3/8 (37.5) | 92/202 (45.5) | |
| 30/72 (41.7) | 28/66 (42.4) | 1/7 (14.3) | 59/145 (40.7) | 31/72 (43.1) | 37/66 (56.1) | 3/7 (42.9) | 71/145 (49.0) | |
| 67/217 (30.9) | 45/124 (36.3) | 2/25 (8.0) | 114/366 (31.2) | 81/217 (37.3) | 58/124 (46.8) | 3/25 (12.0) | 142/366 (38.8) | |
| 2/27 (7.4) | 4/27 (14.8) | |||||||
| 9/32 (28.1) | 12/32 (37.5) | |||||||
| 103/307 (33.6) | 126/307 (41.0) | |||||||
Univariate and multivariate analysis of potential risk factors for 90 day mortality.
| Variable | Univariate analysis OR p-value 95%CI | Multivariate analysis OR p-value 95%CI |
|---|---|---|
| Age | 1.02 0.021 1.00–1.03 | 0.99 0.615 0.97–1.02 |
| Surgical 58/124 (46.8%) | 1.65 0.026 1.06–2.57 | 1.34 0.348 0.72–2.52 |
| Sepsis 102/222 (45.9%) | 2.21 0.001 1.41–3.47 | 1.83 0.066 1.02–3.27 |
| Hypertension 61/152 (40.1%) | 1.10 0.669 0.72–1.68 | 1.04 0.874 0.64–1.90 |
| HIV 30/75 (40.0%) | 1.07 0.801 0.64–1.80 | 1.11 0.929 0.44–2.12 |
| AKI stage | 1.70 0.015 1.11–2.61 | 1.31 0.276 0.81–2.11 |
| Dialysis 96/204 (47.1%) | 2.24 <0.001 1.45–3.47 | 0.78 0.865 0.04–13.99 |
| ICU 92/202 (47.5%) | 1.89 0.004 1.23–2.93 | 1.27 0.408 0.72–2.24 |
| Dialysis + ICU 74/145 (51.0%) | 2.06 0.001 1.33–3.17 | 1.60 0.212 0.77–3.34 |
| First SLEDD 38/72 | 2.04 0.007 1.21–3.44 | 0.80 0.642 0.32–2.02 |
| First CVVHD 23/89 | 2.51 0.008 1.28–4.94 | 2.21 0.179 0.70–7.02 |
| First HD 34/88 | 0.99 0.972 0.61–1.62 | 0.74 0.593 0.24–2.24 |
| Mechanical ventilation 58/107 | 2.76 <0.001 1.69–4.51 | 2.46 0.019 1.41–4.30 |
| Inotropes 43/84 | 2.27 0.001 1.37–3.76 | 1.24 0.618 0.53–2.91 |
| Time to dialysis | 1.14 0.073 0.99–1.32 | 1.93 0.080 0.93–4.03 |
| AKI stage 1 versus stages 2 and 3 combined | 1.87 0.047 1.03–3.47 | 1.20 0.637 0.57–2.60 |